Begoña Canovas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Begoña Canovas has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Angel R. Nebreda
Institute for Research in Biomedicine (IRB Barcelona) The Barcelona Institute of Science and Technology Barcelona Spain
5 shared publications Ana Igea
Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona 08028, Spain
4 shared publications- Adrià Fernández-Torras
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
1 shared publication Akshay K. Ahuja
Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, Zurich CH-8057, Switzerland
1 shared publication- Alessandro A. Sartori
Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland
1 shared publication Alexander Polyzos
Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou St., Athens GR-11527, Greece
1 shared publication
Latest Publications
- Open Access
- 7 March 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (4) , 100527
Characterization of p38α Signaling Networks in Cancer Cells Using Quantitative Proteomics and Phosphoproteomics
- 7 March 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (4) , 100527
Open AccessCharacterization of p38α Signaling Networks in Cancer Cells Using Quantitative Proteomics and Phosphoproteomics
- 16 July 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (29)
MK2 degradation as a sensor of signal intensity that controls stress-induced cell fate
Significance: In response to stress, cells can activate several mechanisms that support functionality and survival. However, strong or persistent stresses usually trigger a deleterious answer that leads to cell death. The protein kinases p38α and MK2 are implicated in a stress-signaling pathway. Here, we characterize a molecular mechanism that helps to translate the stress-induced activation of the p38α–MK2 pathway into appropriate biological responses. We show that MK2-expression levels are regulated by the stress intensity and that degradation of MK2 triggered by ubiquitination is linked to cell death. This mechanism will be valuable to better understand the implication of this signaling pathway in pathologies such as inflammatory diseases and cancer.
- 16 July 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (29)
MK2 degradation as a sensor of signal intensity that controls stress-induced cell fate
Significance: In response to stress, cells can activate several mechanisms that support functionality and survival. However, strong or persistent stresses usually trigger a deleterious answer that leads to cell death. The protein kinases p38α and MK2 are implicated in a stress-signaling pathway. Here, we characterize a molecular mechanism that helps to translate the stress-induced activation of the p38α–MK2 pathway into appropriate biological responses. We show that MK2-expression levels are regulated by the stress intensity and that degradation of MK2 triggered by ubiquitination is linked to cell death. This mechanism will be valuable to better understand the implication of this signaling pathway in pathologies such as inflammatory diseases and cancer.
- Top Cited Papers
- 27 January 2021
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- Vol. 22 (5) , 346-366
Diversity and versatility of p38 kinase signalling in health and disease
The ability of cells to deal with different types of stressful situations in a precise and coordinated manner is key for survival and involves various signalling networks. Over the past 25 years, p38 kinases — in particular, p38α — have been implicated in the cellular response to stress at many levels. These span from environmental and intracellular stresses, such as hyperosmolarity, oxidative stress or DNA damage, to physiological situations that involve important cellular changes such as differentiation. Given that p38α controls a plethora of functions, dysregulation of this pathway has been linked to diseases such as inflammation, immune disorders or cancer, suggesting the possibility that targeting p38α could be of therapeutic interest. In this Review, we discuss the organization of this signalling pathway focusing on the diversity of p38α substrates, their mechanisms and their links to particular cellular functions. We then address how the different cellular responses can be generated depending on the signal received and the cell type, and highlight the roles of this kinase in human physiology and in pathological contexts.
- 27 January 2021
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- Vol. 22 (5) , 346-366
Top Cited PapersDiversity and versatility of p38 kinase signalling in health and disease
The ability of cells to deal with different types of stressful situations in a precise and coordinated manner is key for survival and involves various signalling networks. Over the past 25 years, p38 kinases — in particular, p38α — have been implicated in the cellular response to stress at many levels. These span from environmental and intracellular stresses, such as hyperosmolarity, oxidative stress or DNA damage, to physiological situations that involve important cellular changes such as differentiation. Given that p38α controls a plethora of functions, dysregulation of this pathway has been linked to diseases such as inflammation, immune disorders or cancer, suggesting the possibility that targeting p38α could be of therapeutic interest. In this Review, we discuss the organization of this signalling pathway focusing on the diversity of p38α substrates, their mechanisms and their links to particular cellular functions. We then address how the different cellular responses can be generated depending on the signal received and the cell type, and highlight the roles of this kinase in human physiology and in pathological contexts.
- 1 June 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (6) , 1094-1110.e8
Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells
- 1 June 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (6) , 1094-1110.e8
Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells
- Open Access
- 15 January 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (2) , 459-469
Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Combinatorial therapeutic approaches are an imperative to improve cancer treatment, because it is critical to impede compensatory signaling mechanisms that can engender drug resistance to individual targeted drugs. Currently approved drug combinations result largely from empirical clinical experience and cover only a small fraction of a vast therapeutic space. Here we present a computational network biology approach, based on pathway cross-talk inhibition, to discover new synergistic drug combinations for breast cancer treatment. In silico analysis identified 390 novel anticancer drug pairs belonging to 10 drug classes that are likely to diminish pathway cross-talk and display synergistic antitumor effects. Ten novel drug combinations were validated experimentally, and seven of these exhibited synergy in human breast cancer cell lines. In particular, we found that one novel combination, pairing the estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor cabozantinib, dramatically potentiated the drugs' individual antitumor effects in a mouse model of breast cancer. When compared with high-throughput combinatorial studies without computational prioritization, our approach offers a significant advance capable of uncovering broad-spectrum utility across many cancer types. Cancer Res; 77(2); 459–69. ©2016 AACR.
- 15 January 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (2) , 459-469
Open AccessQuantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Combinatorial therapeutic approaches are an imperative to improve cancer treatment, because it is critical to impede compensatory signaling mechanisms that can engender drug resistance to individual targeted drugs. Currently approved drug combinations result largely from empirical clinical experience and cover only a small fraction of a vast therapeutic space. Here we present a computational network biology approach, based on pathway cross-talk inhibition, to discover new synergistic drug combinations for breast cancer treatment. In silico analysis identified 390 novel anticancer drug pairs belonging to 10 drug classes that are likely to diminish pathway cross-talk and display synergistic antitumor effects. Ten novel drug combinations were validated experimentally, and seven of these exhibited synergy in human breast cancer cell lines. In particular, we found that one novel combination, pairing the estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor cabozantinib, dramatically potentiated the drugs' individual antitumor effects in a mouse model of breast cancer. When compared with high-throughput combinatorial studies without computational prioritization, our approach offers a significant advance capable of uncovering broad-spectrum utility across many cancer types. Cancer Res; 77(2); 459–69. ©2016 AACR.
- Open Access
- 20 June 2016
- Published by Springer Nature in Nature Cell Biology
- Vol. 18 (7) , 777-789
Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing
The cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21) is a cell-cycle checkpoint effector and inducer of senescence, regulated by p53. Yet, evidence suggests that p21 could also be oncogenic, through a mechanism that has so far remained obscure. We report that a subset of atypical cancerous cells strongly expressing p21 showed proliferation features. This occurred predominantly in p53-mutant human cancers, suggesting p53-independent upregulation of p21 selectively in more aggressive tumour cells. Multifaceted phenotypic and genomic analyses of p21-inducible, p53-null, cancerous and near-normal cellular models showed that after an initial senescence-like phase, a subpopulation of p21-expressing proliferating cells emerged, featuring increased genomic instability, aggressiveness and chemoresistance. Mechanistically, sustained p21 accumulation inhibited mainly the CRL4–CDT2 ubiquitin ligase, leading to deregulated origin licensing and replication stress. Collectively, our data reveal the tumour-promoting ability of p21 through deregulation of DNA replication licensing machinery—an unorthodox role to be considered in cancer treatment, since p21 responds to various stimuli including some chemotherapy drugs.
- 20 June 2016
- Published by Springer Nature in Nature Cell Biology
- Vol. 18 (7) , 777-789
Open AccessChronic p53-independent p21 expression causes genomic instability by deregulating replication licensing
The cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21) is a cell-cycle checkpoint effector and inducer of senescence, regulated by p53. Yet, evidence suggests that p21 could also be oncogenic, through a mechanism that has so far remained obscure. We report that a subset of atypical cancerous cells strongly expressing p21 showed proliferation features. This occurred predominantly in p53-mutant human cancers, suggesting p53-independent upregulation of p21 selectively in more aggressive tumour cells. Multifaceted phenotypic and genomic analyses of p21-inducible, p53-null, cancerous and near-normal cellular models showed that after an initial senescence-like phase, a subpopulation of p21-expressing proliferating cells emerged, featuring increased genomic instability, aggressiveness and chemoresistance. Mechanistically, sustained p21 accumulation inhibited mainly the CRL4–CDT2 ubiquitin ligase, leading to deregulated origin licensing and replication stress. Collectively, our data reveal the tumour-promoting ability of p21 through deregulation of DNA replication licensing machinery—an unorthodox role to be considered in cancer treatment, since p21 responds to various stimuli including some chemotherapy drugs.
- Open Access
- 24 September 2013
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 5 (11) , 1759-1774
Inhibition of p38 MAPK sensitizes tumour cells to cisplatin‐induced apoptosis mediated by reactive oxygen species and JNK
The p38 MAPK pathway is an important regulator of many cellular responses. It is well established that p38 MAPK signalling negatively regulates epithelial cell transformation, but enhanced p38 MAPK activity has been also correlated with bad clinical prognosis in some tumour types. Here, we provide genetic and pharmacological evidence showing that p38 MAPK inhibition cooperates with the chemotherapeutic agent cisplatin to kill tumour cells. We show that p38 MAPK inhibition results in ROS upregulation, which in turn activates the JNK pathway via inactivation of phosphatases, sensitizing human tumour cells to cisplatin‐induced apoptosis. Using a mouse model for breast cancer, we confirm that inhibition of p38 MAPK cooperates with cisplatin treatment to reduce tumour size and malignancy in vivo . Taken together, our results illustrate a new function of p38 MAPK that helps tumour cells to survive chemotherapeutic drug treatments, and reveal that the combination of p38 MAPK inhibitors with cisplatin can be potentially exploited for cancer therapy.
- 24 September 2013
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 5 (11) , 1759-1774
Open AccessInhibition of p38 MAPK sensitizes tumour cells to cisplatin‐induced apoptosis mediated by reactive oxygen species and JNK
The p38 MAPK pathway is an important regulator of many cellular responses. It is well established that p38 MAPK signalling negatively regulates epithelial cell transformation, but enhanced p38 MAPK activity has been also correlated with bad clinical prognosis in some tumour types. Here, we provide genetic and pharmacological evidence showing that p38 MAPK inhibition cooperates with the chemotherapeutic agent cisplatin to kill tumour cells. We show that p38 MAPK inhibition results in ROS upregulation, which in turn activates the JNK pathway via inactivation of phosphatases, sensitizing human tumour cells to cisplatin‐induced apoptosis. Using a mouse model for breast cancer, we confirm that inhibition of p38 MAPK cooperates with cisplatin treatment to reduce tumour size and malignancy in vivo . Taken together, our results illustrate a new function of p38 MAPK that helps tumour cells to survive chemotherapeutic drug treatments, and reveal that the combination of p38 MAPK inhibitors with cisplatin can be potentially exploited for cancer therapy.